These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35039052)

  • 1. The SF3B1
    Guo J; Li C; Fang Q; Liu Y; Wang D; Chen Y; Xie W; Zhang Y
    J Exp Clin Cancer Res; 2022 Jan; 41(1):26. PubMed ID: 35039052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic SF3B1 hotspot mutation in prolactinomas.
    Li C; Xie W; Rosenblum JS; Zhou J; Guo J; Miao Y; Shen Y; Wang H; Gong L; Li M; Zhao S; Cheng S; Zhu H; Jiang T; Ling S; Wang F; Zhang H; Zhang M; Qu Y; Zhang Q; Li G; Wang J; Ma J; Zhuang Z; Zhang Y
    Nat Commun; 2020 May; 11(1):2506. PubMed ID: 32427851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant SF3B1 promotes AKT- and NF-κB-driven mammary tumorigenesis.
    Liu B; Liu Z; Chen S; Ki M; Erickson C; Reis-Filho JS; Durham BH; Chang Q; de Stanchina E; Sun Y; Rabadan R; Abdel-Wahab O; Chandarlapaty S
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33031100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances.
    Fuentes-Fayos AC; Pérez-Gómez JM; G-García ME; Jiménez-Vacas JM; Blanco-Acevedo C; Sánchez-Sánchez R; Solivera J; Breunig JJ; Gahete MD; Castaño JP; Luque RM
    J Exp Clin Cancer Res; 2022 Jan; 41(1):39. PubMed ID: 35086552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knockdown of SF3B1 inhibits cell proliferation, invasion and migration triggering apoptosis in breast cancer via aberrant splicing.
    Zhang L; Zhang X; Zhang H; Liu F; Bi Y; Zhang Y; Cheng C; Liu J
    Breast Cancer; 2020 May; 27(3):464-476. PubMed ID: 31919642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability.
    Liberante FG; Lappin K; Barros EM; Vohhodina J; Grebien F; Savage KI; Mills KI
    Sci Rep; 2019 Feb; 9(1):2678. PubMed ID: 30804405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Screening of drugs that selectively inhibit uveal melanoma cells with SF3B1 mutations].
    Luo X; Ren C; Liu X; Zhang G; Huang S; Yu L; Li Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Dec; 41(12):1835-1842. PubMed ID: 35012916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the aberrant splicing of MAP3K7 induced by cancer-associated SF3B1 mutation.
    Li Z; Zhao B; Shi Y; Liang Y; Qian R; Wan Y
    J Biochem; 2021 Sep; 170(1):69-77. PubMed ID: 33751071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A-c-Myc axis.
    Yang JY; Huo YM; Yang MW; Shen Y; Liu DJ; Fu XL; Tao LY; He RZ; Zhang JF; Hua R; Jiang SH; Sun YW; Liu W
    Mol Oncol; 2021 Nov; 15(11):3076-3090. PubMed ID: 33932092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations of GNAQ, GNA11, SF3B1, EIF1AX, PLCB4 and CYSLTR in Uveal Melanoma in Chinese Patients.
    Hou C; Xiao L; Ren X; Tang F; Guo B; Zeng W; Liang C; Yan N
    Ophthalmic Res; 2020; 63(3):358-368. PubMed ID: 31614358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic testing in prolactinomas: a cohort study.
    Boukerrouni A; Cuny T; Anjou T; Raingeard I; Ferrière A; Grunenwald S; Maïza JC; Marquant E; Sahakian N; Fodil-Cherif S; Salle L; Niccoli P; Randrianaivo H; Sonnet E; Chevalier N; Thuillier P; Vezzosi D; Reynaud R; Dufour H; Brue T; Tabarin A; Delemer B; Kerlan V; Castinetti F; Barlier A; Romanet P
    Eur J Endocrinol; 2023 Dec; 189(6):567-574. PubMed ID: 37956455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. U2AF65-Dependent SF3B1 Function in SMN Alternative Splicing.
    Choi N; Liu Y; Oh J; Ha J; Zheng X; Shen H
    Cells; 2020 Dec; 9(12):. PubMed ID: 33317029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Splicing Factor 3b Subunit 1 (SF3B1) Reduced Cell Proliferation, Induced Apoptosis and Resulted in Cell Cycle Arrest by Regulating Homeobox A10 (HOXA10) Splicing in AGS and MKN28 Human Gastric Cancer Cells.
    Zhang Y; Yuan Z; Jiang Y; Shen R; Gu M; Xu W; Gu X
    Med Sci Monit; 2020 Jan; 26():e919460. PubMed ID: 31927557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SF3B1 mutant myelodysplastic syndrome: Recent advances.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2021 Jan; 79():100776. PubMed ID: 33358369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant SF3B1 promotes malignancy in PDAC.
    Simmler P; Ioannidi EI; Mengis T; Marquart KF; Asawa S; Van-Lehmann K; Kahles A; Thomas T; Schwerdel C; Aceto N; Rätsch G; Stoffel M; Schwank G
    Elife; 2023 Oct; 12():. PubMed ID: 37823551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Splicing factor SF3B1K700E mutant dysregulates erythroid differentiation via aberrant alternative splicing of transcription factor TAL1.
    Jin S; Su H; Tran NT; Song J; Lu SS; Li Y; Huang S; Abdel-Wahab O; Liu Y; Zhao X
    PLoS One; 2017; 12(5):e0175523. PubMed ID: 28545085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GPATCH8 modulates mutant SF3B1 mis-splicing and pathogenicity in hematologic malignancies.
    Benbarche S; Pineda JMB; Galvis LB; Biswas J; Liu B; Wang E; Zhang Q; Hogg SJ; Lyttle K; Dahi A; Lewis AM; Sarchi M; Rahman J; Fox N; Ai Y; Mehta S; Garippa R; Ortiz-Pacheco J; Li Z; Monetti M; Stanley RF; Doulatov S; Bradley RK; Abdel-Wahab O
    Mol Cell; 2024 May; 84(10):1886-1903.e10. PubMed ID: 38688280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SF3B1 mutations constitute a novel therapeutic target in breast cancer.
    Maguire SL; Leonidou A; Wai P; Marchiò C; Ng CK; Sapino A; Salomon AV; Reis-Filho JS; Weigelt B; Natrajan RC
    J Pathol; 2015 Mar; 235(4):571-80. PubMed ID: 25424858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3' splice sites within RNA secondary structures.
    Kesarwani AK; Ramirez O; Gupta AK; Yang X; Murthy T; Minella AC; Pillai MM
    Oncogene; 2017 Feb; 36(8):1123-1133. PubMed ID: 27524419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-associated mutations in SF3B1 disrupt the interaction between SF3B1 and DDX42.
    Zhao B; Li Z; Qian R; Liu G; Fan M; Liang Z; Hu X; Wan Y
    J Biochem; 2022 Jul; 172(2):117-126. PubMed ID: 35652295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.